Celltrion begins global supply of COVID-19 antibody treatment
(VOVWORLD) -South Korean pharmaceutical giant Celltrion Inc. has begun the global supply of its COVID-19 antibody treatment starting with Pakistan, according to the company's affiliate on Monday.
 Rekirona for COVID-19 treatment produced by the South Korean pharmaceutical giant Celltrion Inc. (Photo: Pulse News / VNA) |
Celltrion Healthcare, which handles Celltrion's overseas business, said it has signed a contract with a Pakistan state-run company to export 100,000 tablets of Rekirona, which is enough for 30,000 people. A company official said that talks are currently under way to export Rekirona to other countries in Europe and South America, as well as India.
Rekirona won the South Korean drug safety agency's conditional approval in February, becoming the first locally made treatment for COVID-19.
Celltrion said it has also completed a global phase-three clinical trial, a pivotal part of the study, in more than 10 countries to obtain more comprehensive safety and efficacy results of the COVID-19 treatment.